<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584725</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM9601</org_study_id>
    <nct_id>NCT02584725</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Dosing for Total Joint Arthroplasty</brief_title>
  <official_title>Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of increasing doses of tranexamic acid&#xD;
      (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a&#xD;
      change in hemoglobin from pre-operative baseline to the first post-operative day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, double-blinded trial comparing three different doses&#xD;
      of TXA (5mg/kg, 10mg/kg, 15mg/kg) in decreasing blood loss during and after total knee and&#xD;
      total hip arthroplasty. Patients undergoing total knee arthroplasty and total hip&#xD;
      arthroplasty will be analyzed separately, in sub-group analysis. The primary endpoint will be&#xD;
      the change in hemoglobin from baseline to the first post-operative day (POD#1).&#xD;
&#xD;
      Patients will initially be identified by their orthopedic surgeon if they meet the inclusion&#xD;
      and exclusion criteria. They will be informed about the study and provided with the consent&#xD;
      form in the office, which they will be able to review further prior to the date of surgery.&#xD;
      If the patient wishes to participate, formal written consent will be completed by one of the&#xD;
      study investigators or a member of the regional anesthesia team. Patients will then be&#xD;
      randomized to one of three groups. The anesthesia team responsible for the subject patient's&#xD;
      care will receive two twenty milliliter syringes of medication. The syringe labeled &quot;Study&#xD;
      medication #1&quot; will be administered intravenously over 20 minutes beginning at the start of&#xD;
      surgical skin preparation, and the syringe labeled &quot;Study medication #2&quot; will be administered&#xD;
      over 20 minutes beginning at the start of surgical wound closure. The syringes for group 1&#xD;
      (low-dose TXA) will each contain 5mg/kg TXA, diluted to 20 milliliters with saline. The&#xD;
      syringes for group 2 (moderate-dose TXA) will each contain 10mg/kg TXA, diluted to 20&#xD;
      milliliters with saline. The syringes for group 3 (high-dose TXA) will each contain 15mg/kg&#xD;
      TXA, diluted to 20 milliliters with saline. The anesthesia team will document the total&#xD;
      intra-operative estimated blood loss as well as the amount of blood in the suction canister&#xD;
      at the end of the surgery (as calculated by volume in the suction bucket minus volume of&#xD;
      irrigation used).&#xD;
&#xD;
      The intraoperative course will be standardized for all patients included in the study. For&#xD;
      total knee arthroplasty patients, the anesthesia will consist of a long-acting femoral or&#xD;
      adductor canal peripheral nerve block, followed by a standardized spinal anesthetic using&#xD;
      15mg of plain isobaric bupivacaine. For total hip arthroplasty patients, the anesthesia will&#xD;
      consist of a standardized spinal anesthetic using 15mg of plain isobaric bupivacaine. In&#xD;
      those patients for whom spinal anesthesia is contraindicated or refused, general anesthesia&#xD;
      will be performed and these patients will be excluded from the study. All patients initially&#xD;
      enrolled, but excluded secondary to administration of a general anesthetic will be analyzed&#xD;
      via an intention-to-treat method. Administration of intravenous crystalloid solutions will be&#xD;
      per the discretion of the anesthesia team participating in the intra-operative portion of&#xD;
      each patient's care, and will be documented for purposes of this study by the anesthesia&#xD;
      team.&#xD;
&#xD;
      On PODs #0, #1 and #2, all patients will undergo standard post-operative blood work which&#xD;
      includes a complete blood count. When working with physical therapy on POD#1 and POD#2,&#xD;
      assessment of ability to sit, stand, and walk (yes/no) will be recorded. Assessment of pain&#xD;
      scores via a VAS (0-10 scale, with 0 being no pain and 10 being the worst 05/26/2016 pain)&#xD;
      will be recorded on POD#1 and POD#2. Assessment of subjective sense of overall wellbeing (a&#xD;
      0-10 scale, with 0 being the worst patients have ever felt, and 10 representing pre-operative&#xD;
      baseline) will be recorded on POD #1 and #2. Patients will also be monitored via clinical&#xD;
      exam for incidence of seizure, transient ischemic attack, stroke, myocardial infarction, deep&#xD;
      venous thrombosis, and pulmonary embolus in the first 48 post-operatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin From Baseline to POD#0</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin From Baseline to POD#2</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Blood Transfusion From the Intra-operative Period Into the End of POD#2</measure>
    <time_frame>2 days</time_frame>
    <description>Number or count of participants requiring transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Estimated Intra-operative Blood Loss</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood in the Surgical Suction Canister at the End of Surgery</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Able to Sit on Post-Operative Day 1 (POD1) and Post-Operative Day 2 (POD2)</measure>
    <time_frame>2 days</time_frame>
    <description>Count of participants able to sit on POD1 and POD2 as assessed by a mobility assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Able to Stand on POD1 and POD2</measure>
    <time_frame>2 days</time_frame>
    <description>Count of participants able to stand on POD1 and POD2 as assessed by a mobility assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Able to Walk on POD1 and POD2</measure>
    <time_frame>2 days</time_frame>
    <description>Count of participants able to Walk on POD1 and POD2 as assessed by a mobility assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Scores on POD#1 and POD#2</measure>
    <time_frame>2 days</time_frame>
    <description>The VAS measures pain on a scale of 0-10, with 0=no pain and 10=worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellbeing Questionnaire Score on POD#1 and POD#2</measure>
    <time_frame>2 days</time_frame>
    <description>Patients' self-reported scores on a scale of overall feeling of wellbeing on POD#1 and POD#2. Scores range from 0-10, with 0= &quot;worst I have ever felt&quot; and 10= &quot;feel just as well as before surgery.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Seizure, Transient Ischemic Attack, Stroke, Myocardial Infarction, Deep Venous Thrombosis, and Pulmonary Embolus</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Arthropathy of Hip</condition>
  <condition>Arthropathy of Knee</condition>
  <arm_group>
    <arm_group_label>5 mg/kg/dose tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg/dose tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg/kg/dose tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Comparison of 3 different doses of the drug</description>
    <arm_group_label>10 mg/kg/dose tranexamic acid</arm_group_label>
    <arm_group_label>15 mg/kg/dose tranexamic acid</arm_group_label>
    <arm_group_label>5 mg/kg/dose tranexamic acid</arm_group_label>
    <other_name>Lysteda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing primary unilateral total knee arthroplasty or primary unilateral&#xD;
             total hip arthroplasty under spinal anesthesia at Columbia University Medical Center/&#xD;
             New York Presbyterian Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking.&#xD;
&#xD;
          -  Patient refusal to participate.&#xD;
&#xD;
          -  Weight exceeding 100kg.&#xD;
&#xD;
          -  Baseline hemoglobin of less than 10.&#xD;
&#xD;
          -  Repeat, revision, or bilateral surgery.&#xD;
&#xD;
          -  Known sensitivity or allergy to Tranexamic Acid.&#xD;
&#xD;
          -  Active intra-vascular clotting.&#xD;
&#xD;
          -  History of coagulopathy or congenital thrombophilia.&#xD;
&#xD;
          -  Thromboembolic event in the 12 months prior to enrollment.&#xD;
&#xD;
          -  Percutaneous coronary intervention requiring a drug eluting stent in the 12 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  History of anticoagulant medication use unless stopped prior to surgery as recommended&#xD;
             by and in accordance with the American Society of Regional Anesthesia Guidelines.&#xD;
&#xD;
          -  Use of a general anesthetic in the current anesthetic.&#xD;
&#xD;
          -  Blood transfusion for a hemoglobin value which deviates from the study's transfusion&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Maniker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Robert Maniker</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Total Joint Arthroplasty</keyword>
  <keyword>Intraoperative Blood Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02584725/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5 mg/kg/Dose Tranexamic Acid</title>
          <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="P2">
          <title>10 mg/kg/Dose Tranexamic Acid</title>
          <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="P3">
          <title>15 mg/kg/Dose Tranexamic Acid</title>
          <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg/kg/Dose Tranexamic Acid</title>
          <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="B2">
          <title>10 mg/kg/Dose Tranexamic Acid</title>
          <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="B3">
          <title>15 mg/kg/Dose Tranexamic Acid</title>
          <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1)</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1)</title>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.19"/>
                    <measurement group_id="O2" value="2.06" spread="0.81"/>
                    <measurement group_id="O3" value="2.11" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin From Baseline to POD#0</title>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to POD#0</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.19"/>
                    <measurement group_id="O2" value="1.30" spread="0.71"/>
                    <measurement group_id="O3" value="1.16" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin From Baseline to POD#2</title>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to POD#2</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.2"/>
                    <measurement group_id="O2" value="2.59" spread="0.67"/>
                    <measurement group_id="O3" value="2.28" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Blood Transfusion From the Intra-operative Period Into the End of POD#2</title>
        <description>Number or count of participants requiring transfusion.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Blood Transfusion From the Intra-operative Period Into the End of POD#2</title>
          <description>Number or count of participants requiring transfusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Estimated Intra-operative Blood Loss</title>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Total Estimated Intra-operative Blood Loss</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.43" spread="276.21"/>
                    <measurement group_id="O2" value="322.32" spread="261.84"/>
                    <measurement group_id="O3" value="376.25" spread="314.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood in the Surgical Suction Canister at the End of Surgery</title>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood in the Surgical Suction Canister at the End of Surgery</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.50" spread="262.19"/>
                    <measurement group_id="O2" value="283.93" spread="240.31"/>
                    <measurement group_id="O3" value="329.11" spread="285.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Able to Sit on Post-Operative Day 1 (POD1) and Post-Operative Day 2 (POD2)</title>
        <description>Count of participants able to sit on POD1 and POD2 as assessed by a mobility assessment.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Able to Sit on Post-Operative Day 1 (POD1) and Post-Operative Day 2 (POD2)</title>
          <description>Count of participants able to sit on POD1 and POD2 as assessed by a mobility assessment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Count of Participants Able to Sit POD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Count of Participants Able to Sit POD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Able to Stand on POD1 and POD2</title>
        <description>Count of participants able to stand on POD1 and POD2 as assessed by a mobility assessment.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Able to Stand on POD1 and POD2</title>
          <description>Count of participants able to stand on POD1 and POD2 as assessed by a mobility assessment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Count of Participants Able to Stand POD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Count of Participants Able to Stand POD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Able to Walk on POD1 and POD2</title>
        <description>Count of participants able to Walk on POD1 and POD2 as assessed by a mobility assessment.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Able to Walk on POD1 and POD2</title>
          <description>Count of participants able to Walk on POD1 and POD2 as assessed by a mobility assessment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Count of Participants Able to Walk POD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Count of Participants Able to Walk POD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain Scores on POD#1 and POD#2</title>
        <description>The VAS measures pain on a scale of 0-10, with 0=no pain and 10=worst possible pain.</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain Scores on POD#1 and POD#2</title>
          <description>The VAS measures pain on a scale of 0-10, with 0=no pain and 10=worst possible pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Pain Score POD#1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="2.76"/>
                    <measurement group_id="O2" value="3.82" spread="2.98"/>
                    <measurement group_id="O3" value="4.36" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Pain Score POD#2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="2.62"/>
                    <measurement group_id="O2" value="3.89" spread="2.69"/>
                    <measurement group_id="O3" value="4.32" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wellbeing Questionnaire Score on POD#1 and POD#2</title>
        <description>Patients' self-reported scores on a scale of overall feeling of wellbeing on POD#1 and POD#2. Scores range from 0-10, with 0= &quot;worst I have ever felt&quot; and 10= &quot;feel just as well as before surgery.&quot;</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Wellbeing Questionnaire Score on POD#1 and POD#2</title>
          <description>Patients' self-reported scores on a scale of overall feeling of wellbeing on POD#1 and POD#2. Scores range from 0-10, with 0= &quot;worst I have ever felt&quot; and 10= &quot;feel just as well as before surgery.&quot;</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wellbeing Score POD#1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="2.91"/>
                    <measurement group_id="O2" value="7.71" spread="2.62"/>
                    <measurement group_id="O3" value="7.04" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wellbeing Score POD#2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" spread="2.96"/>
                    <measurement group_id="O2" value="8.04" spread="2.08"/>
                    <measurement group_id="O3" value="7.39" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Seizure, Transient Ischemic Attack, Stroke, Myocardial Infarction, Deep Venous Thrombosis, and Pulmonary Embolus</title>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg/kg/Dose Tranexamic Acid</title>
            <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O2">
            <title>10 mg/kg/Dose Tranexamic Acid</title>
            <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
          <group group_id="O3">
            <title>15 mg/kg/Dose Tranexamic Acid</title>
            <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Seizure, Transient Ischemic Attack, Stroke, Myocardial Infarction, Deep Venous Thrombosis, and Pulmonary Embolus</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-operative Seizure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative Pulmonary Embolus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 Days</time_frame>
      <desc>Monitoring of potential adverse events will be done via clinical exam in the first 48 hours post-operatively. The definition of adverse event does not differ from the ClinicalTrials.gov definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>5 mg/kg/Dose Tranexamic Acid</title>
          <description>5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="E2">
          <title>10 mg/kg/Dose Tranexamic Acid</title>
          <description>10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
        <group group_id="E3">
          <title>15 mg/kg/Dose Tranexamic Acid</title>
          <description>15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Maniker, MD</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>212-305-9876</phone>
      <email>rm3046@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

